Aclaris Therapeutics Inc (NASDAQ: ACRS) started the day on Thursday, with a price decrease of -7.63% at $3.27, before settling in for the price of $3.54 at the close. Taking a more long-term approach, ACRS posted a 52-week range of $0.80-$5.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 74.29%. Meanwhile, its Annual Earning per share during the time was 20.67%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 41.73%. This publicly-traded company’s shares outstanding now amounts to $71.42 million, simultaneously with a float of $59.89 million. The organization now has a market capitalization sitting at $233.58 million. At the time of writing, stock’s 50-day Moving Average stood at $2.45, while the 200-day Moving Average is $1.52.
Aclaris Therapeutics Inc (ACRS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Diagnostics & Research Industry. Aclaris Therapeutics Inc’s current insider ownership accounts for 16.15%, in contrast to 75.64% institutional ownership. According to the most recent insider trade that took place on Nov 19 ’24, this organization’s Director bought 666,666 shares at the rate of 2.25, making the entire transaction reach 1,499,998 in total value, affecting insider ownership by 710,030. Preceding that transaction, on Aug 05 ’24, Company’s 10% Owner bought 206,025 for 1.24, making the whole transaction’s value amount to 256,357. This particular insider is now the holder of 14,250,000 in total.
Aclaris Therapeutics Inc (ACRS) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
Aclaris Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 41.73% and is forecasted to reach -0.52 in the upcoming year.
Aclaris Therapeutics Inc (NASDAQ: ACRS) Trading Performance Indicators
Let’s observe the current performance indicators for Aclaris Therapeutics Inc (ACRS). It’s Quick Ratio in the last reported quarter now stands at 7.03. The Stock has managed to achieve an average true range (ATR) of 0.38. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.63.
In the same vein, ACRS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.52, a figure that is expected to reach -0.25 in the next quarter, and analysts are predicting that it will be -0.52 at the market close of one year from today.
Technical Analysis of Aclaris Therapeutics Inc (ACRS)
If we take a close look at the recent performances of Aclaris Therapeutics Inc (NASDAQ: ACRS), its last 5-days Average volume was 0.81 million that shows plunge from its year to date volume of 1.39 million. During the previous 9 days, stock’s Stochastic %D was recorded 7.88% While, its Average True Range was 0.38.
Raw Stochastic average of Aclaris Therapeutics Inc (ACRS) in the period of the previous 100 days is set at 53.09%, which indicates a major rise in contrast to 0.85% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 88.89% that was lower than 120.13% volatility it exhibited in the past 100-days period.
